These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17910205)

  • 1. Pharmacologic treatment of autism and related disorders.
    Erickson CA; Posey DJ; Stigler KA; McDougle CJ
    Pediatr Ann; 2007 Sep; 36(9):575-85. PubMed ID: 17910205
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
    Adler BA; Wink LK; Early M; Shaffer R; Minshawi N; McDougle CJ; Erickson CA
    Autism; 2015 Jan; 19(1):102-6. PubMed ID: 24571823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
    Demb HB
    J Child Adolesc Psychopharmacol; 1996; 6(1):79-80. PubMed ID: 9231302
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
    McDougle CJ; Stigler KA; Erickson CA; Posey DJ
    J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
    Findling RL
    J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonidine: diverse use in pharmacologic management.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2011 Apr; 47(2):105-8. PubMed ID: 21426356
    [No Abstract]   [Full Text] [Related]  

  • 9. Secretin treatment for autism.
    Rimland B
    N Engl J Med; 2000 Apr; 342(16):1216-7; author reply 1218. PubMed ID: 10777377
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiepileptic drugs: affective use in autism spectrum disorders.
    Di Martino A; Tuchman RF
    Pediatr Neurol; 2001 Sep; 25(3):199-207. PubMed ID: 11587873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
    Leskovec TJ; Rowles BM; Findling RL
    Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing drugs for core social and communication impairment in autism.
    Posey DJ; Erickson CA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):787-801, viii-ix. PubMed ID: 18775370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of pervasive developmental disorders].
    Fuentes J; Gallano I
    Rev Neurol; 2001 Aug 1-15; 33(3):208-10. PubMed ID: 11588711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of risperidone in children with autism spectrum disorder.
    Chavez B; Chavez-Brown M; Rey JA
    Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The autistic-spectrum disorders.
    Rapin I
    N Engl J Med; 2002 Aug; 347(5):302-3. PubMed ID: 12151466
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment options for the management of pervasive developmental disorders.
    Nash K; Carter KJ
    Int J Psychiatry Med; 2016; 51(2):201-10. PubMed ID: 27079778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic medicine in autism: challenges and opportunities.
    Bowers K; Lin PI; Erickson C
    Paediatr Drugs; 2015 Apr; 17(2):115-24. PubMed ID: 25420674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
    Sandler AD; Sutton KA; DeWeese J; Girardi MA; Sheppard V; Bodfish JW
    N Engl J Med; 1999 Dec; 341(24):1801-6. PubMed ID: 10588965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self injurious behavior in autism: clinical aspects and treatment with risperidone.
    Canitano R
    J Neural Transm (Vienna); 2006 Mar; 113(3):425-31. PubMed ID: 16075185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder.
    Kern JK; Miller VS; Cauller PL; Kendall PR; Mehta PJ; Dodd M
    J Child Neurol; 2001 Mar; 16(3):169-73. PubMed ID: 11305684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.